Expert Outlook: RxSight Through The Eyes Of 5 Analysts
Across the recent three months, 5 analysts have shared their insights on RxSight (NASDAQ:RXST), expressing a variety of opinions spanning from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 1 | 0 | 3 | 1 | 0 |
| Last 30D | 0 | 0 | 1 | 0 | 0 |
| 1M Ago | 0 | 0 | 0 | 0 | 0 |
| 2M Ago | 0 | 0 | 1 | 0 | 0 |
| 3M Ago | 1 | 0 | 1 | 1 | 0 |
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $10.4, a high estimate of $12.00, and a low estimate of $9.00. This current average reflects an increase of 10.64% from the previous average price target of $9.40.
Interpreting Analyst Ratings: A Closer Look
A clear picture of RxSight's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Adam Maeder | Piper Sandler | Raises | Neutral | $11.00 | $10.00 |
| Patrick Wood | Morgan Stanley | Raises | Equal-Weight | $10.00 | $9.00 |
| Robbie Marcus | JP Morgan | Raises | Underweight | $9.00 | $8.00 |
| Larry Biegelsen | Wells Fargo | Raises | Equal-Weight | $10.00 | $9.00 |
| David Saxon | Needham | Raises | Buy | $12.00 | $11.00 |
Key Insights:
- Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to RxSight. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of RxSight compared to the broader market.
- Price Targets: Gaining insights, analysts provide estimates for the future value of RxSight's stock. This comparison reveals trends in analysts' expectations over time.
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of RxSight's market standing. Stay informed and make data-driven decisions with our Ratings Table.
Stay up to date on RxSight analyst ratings.
If you are interested in following small-cap stock news and performance you can start by tracking it here.
Delving into RxSight's Background
RxSight Inc is a commercial-stage medical technology company dedicated towards improving the vision of patients following cataract surgery. It offers intraocular lens technology that enables doctors to customize and optimize visual acuity for patients after cataract surgery. The company operates and manages its business in one reportable segment, the research and development, manufacture and sale of light adjustable lenses and related capital equipment.
Financial Milestones: RxSight's Journey
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Negative Revenue Trend: Examining RxSight's financials over 3M reveals challenges. As of 30 September, 2025, the company experienced a decline of approximately -14.09% in revenue growth, reflecting a decrease in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: RxSight's net margin is below industry averages, indicating potential challenges in maintaining strong profitability. With a net margin of -32.35%, the company may face hurdles in effective cost management.
Return on Equity (ROE): RxSight's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of -3.54%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): RxSight's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of -3.18%, the company may face hurdles in achieving optimal financial performance.
Debt Management: With a below-average debt-to-equity ratio of 0.04, RxSight adopts a prudent financial strategy, indicating a balanced approach to debt management.
What Are Analyst Ratings?
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
This article was generated by Benzinga's automated content engine and reviewed by an editor.